Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

    June 2021 in “ Journal of The American Academy of Dermatology ”
    Brett King, Justin Ko, Seth Forman … Yves Dutronc
    Studysummary In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 15

    1. Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata American Journal of Clinical Dermatology · 2020
    2. The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials British Journal of Dermatology · 2020
    3. Treatment of Severe Alopecia Areata with Baricitinib JAAD Case Reports · 2019
    4. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    5. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    6. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    7. Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents Journal of the American Academy of Dermatology · 2016
    8. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    9. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    10. Health-Related Quality of Life Among Patients With Alopecia Areata: A Systematic Review Journal of The American Academy of Dermatology · 2016
    11. Alopecia Areata and Health-Related Quality of Life: A Systematic Review and Meta-Analysis British Journal of Dermatology · 2016
    12. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    13. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014
    14. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    15. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014

    Related research 3

    1. Sensitive Scalp: An Epidemiologic Study in Patients with Hair Loss Dermatology Reports · 2022
    2. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019
    3. Comparison of the Therapeutic Effect of 2% Topical Minoxidil with Rosemary Solution in the Treatment of Alopecia Areata on the Scalp DOAJ (DOAJ: Directory of Open Access Journals) · 2014